Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 65,148 shares of the company's stock, valued at approximately $2,372,000. Harmony Biosciences accounts for approximately 1.2% of

Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.

California State Teachers Retirement System raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 40.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 57,928 shares of the company's stock after purchasing an additional 16,821 shares during

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

Stocks like SNX, AMP, HRMY and NWL are seeing price strength and have a high chance of carrying the momentum forward.

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

Harmony Biosciences (NASDAQ: HRMY) reported second-quarter net revenue of $261.3 million, up 30% from the prior-year period and 21% sequentially, as sales of its narcolepsy treatment WAKIX rebounded from seasonal market-access pressures earlier in the year. The company reiterated its 2026 net revenue guidance of $1 billion to $1.04 billion. Net income for the quarter rose

Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.